Coronavirus Vaccine
/ AuraVax Therap, University of Houston
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
February 03, 2021
AuraVax Therapeutics Enters into Exclusive License Agreement with the University of Houston for Intranasal Vaccine and Therapeutics Technology Platform
(PRNewswire)
- "AuraVax Therapeutics Inc....announced it has entered into an exclusive license agreement with the University of Houston (UH) with respect to the intellectual property covering a novel intranasal vaccine and STING agonist technologies. This agreement converts the optioned intellectual property between UH and AuraVax announced on October 12, 2020."
Licensing / partnership • Infectious Disease • Novel Coronavirus Disease
January 13, 2021
AuraVax Therapeutics Enters into Exclusive License Agreement with Massachusetts General Hospital for Intranasal Vaccine and Therapeutics Platform
(PRNewswire)
- "AuraVax Therapeutics Inc....announced it has entered into an exclusive license agreement with Massachusetts General Hospital (MGH) covering certain intellectual property and technology rights regarding compositions and discoveries of liposomal STING agonists by Mei X. Wu, PhD, of the Wellman Center for Photomedicine at MGH....'The intellectual property expands our portfolio to broadly target respiratory diseases from both a vaccine and therapeutic perspective. We plan to stop COVID-19, a respiratory virus, at its point of entry -- the nasal cavity -- as well as provide systemic protection.'"
Licensing / partnership • Infectious Disease • Novel Coronavirus Disease
1 to 2
Of
2
Go to page
1